Anti-Dcp2/TDT antibody [EPR25378-93] - BSA and Azide free,Abcam,AB288165
ab288165 is the carrier-free version of ab288158 Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Conjugation ready Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications. Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold. Compatibility This product is compatible with the Maxpar ® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar ® is a trademark of Fluidigm Canada Inc.
Host
Rabbit
Reactivity
Rat, Mouse, Human
Application
Flow Cyt (Intra), IP, WB
Platform ID
BAB153847940
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Decapping metalloenzyme that catalyzes the cleavage of the cap structure on mRNAs (PubMed : 12218187, PubMed : 12417715, PubMed : 12923261, PubMed : 21070968, PubMed : 28002401, PubMed : 31875550). Removes the 7-methyl guanine cap structure from mRNA molecules, yielding a 5'-phosphorylated mRNA fragment and 7m-GDP (PubMed : 12486012, PubMed : 12923261, PubMed : 21070968, PubMed : 28002401, PubMed : 31875550). Necessary for the degradation of mRNAs, both in normal mRNA turnover and in nonsense-mediated mRNA decay (PubMed : 14527413). Plays a role in replication-dependent histone mRNA degradation (PubMed : 18172165). Has higher activity towards mRNAs that lack a poly(A) tail (PubMed : 21070968). Has no activity towards a cap structure lacking an RNA moiety (PubMed : 21070968). The presence of a N(6)-methyladenosine methylation at the second transcribed position of mRNAs (N(6),2'-O-dimethyladenosine cap; m6A(m)) provides resistance to DCP2-mediated decapping (PubMed : 28002401). Blocks autophagy in nutrient-rich conditions by repressing the expression of ATG-related genes through degradation of their transcripts (PubMed : 26098573). See full target information DCP2
Category Paths
Please provide the required information below so that we can quickly source your products.